New Clinical Trials Offer Opportunities to Advance Type 1 Diabetes Research

Clinical trials are essential for developing new treatments and understanding how to better manage Type 1 diabetes. By studying investigational medicines in carefully controlled settings, researchers gather safety and effectiveness data that could eventually benefit the broader Type 1 diabetes community. If you've considered participating in research, now may be an opportunity to explore trials actively recruiting in your region.

One trial is evaluating an investigational medicine called rezpegaldesleukin (rezpeg) to see whether it can help preserve insulin secretion after a Type 1 diabetes diagnosis. In this study, participants receive rezpeg as an injection every two weeks for six months, followed by a six-month monitoring period after treatment ends. The research team is examining the medicine's safety, tolerability, and how well it works to maintain insulin production.

Another trial is investigating CNP-103, described as a first-in-class antigen-specific therapy. The study is examining whether CNP-103 can preserve insulin production by targeting the autoimmune attack on beta cells—the cells in the pancreas that produce insulin. Researchers hope that by protecting these cells, the treatment might improve blood sugar control and long-term outcomes for people with Type 1 diabetes. This trial is enrolling participants at multiple sites, including the University of Washington in Seattle.

The Greater Northwest Chapter provides free clinical trial education and support through their Clinical Trial Education Volunteers (CTEV). If you have questions about which trials might be appropriate for you or want to learn more about the research, you can reach out to the chapter's resources at 1-800-888-4187 or contact them via email. The team can help you understand your options and answer specific questions about individual studies. The chapter also hosts a Pacific Northwest Research & Clinical Trials Quarterly Update with detailed information about active trials and recent Type 1 diabetes research developments.

Origin: Greater Northwest Chapter (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.